XBI145.88 −3.10%IBB207.98 −2.13%S&P 5007,416.59 −1.92%NASDAQ 10027,197.15 −2.67%DOW 3051,608.17 −1.41%FTSE 10010,803.40 −0.72%
Biotech Today Subscribe

Bio Space · Brain & Mental Health

Alexandria Highlights Three-Year Depression Research Pilot

Alexandria highlights a depression research partnership and New York biotech investments, including a $381 million IPO and a $14.6 billion acquisition.

Lucas Ferreira · 3 min read
Alexandria Highlights Three-Year Depression Research Pilot

Key facts

  • Listed company: Alexandria Real Estate Equities (NYSE: ARE)
  • MAP-D milestone: Design phase completed in June 2026; three-year pilot planned
  • Venture portfolio acquisition: Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion in 2025
  • Portfolio company IPO: Eikon Therapeutics completed a $381 million IPO in February 2026

Alexandria Real Estate Equities said the MAP-D depression research initiative, which it helped fund and launch, completed its design phase in June 2026 and is advancing toward a three-year pilot.

Alexandria Real Estate Equities, Inc. (NYSE: ARE) is highlighting a depression research partnership that pairs its financial support with a planned three-year study using artificial intelligence to examine links between biological markers and patient outcomes.

The real estate company's role in the Multi-Modal Assessment and Phenotyping in Depression initiative, known as MAP-D, extends beyond providing laboratory space. Alexandria said it supplied the initiative's first funding and helped assemble the cross-sector support needed to launch the public-private partnership with the Foundation for the National Institutes of Health, or FNIH.

Alexandria outlined the work in an announcement carried by PR Newswire on October 29, marking the Prix Galien USA's 20th anniversary in New York City and its longstanding partnership with the Galien Foundation.

Depression project moves beyond study design

MAP-D completed its critical design phase in June 2026 and began advancing toward a longitudinal clinical study, which follows participants over time. The planned research will combine biological measurements, clinical information, brain imaging, digital data and information reported by patients.

MAP-D completed its critical design phase in June 2026 and began advancing toward a longitudinal clinical study, which follows participants over time.

The three-year pilot is intended to use advanced artificial intelligence models to identify relationships between biological markers and patient outcomes. Its longer-term goal is a precision-medicine framework for depression: an approach that could help researchers distinguish patient characteristics relevant to treatment rather than treating depression as a uniform condition.

That remains a research objective, not a demonstrated clinical result. Completion of the design phase marks progress toward conducting the study; it does not establish that the proposed models can guide treatment. Alexandria identified funding, required approvals, participant recruitment and retention, and scientific and operational challenges among the risks to the initiative's timing and execution.

At the Galien Forum USA, Alexandria said it would lead a MAP-D panel co-moderated by executive chairman and founder Joel S. Marcus and chief of science Lynne Zydowsky. Participants include neuroscience, patient-care, policy and drug-development specialists, connecting the research design with the people who could eventually apply its findings.

New York investments provide a separate measure of progress

Alexandria's New York life-science activities also include venture financing and facilities for biotechnology companies. Its venture arm participated in Intra-Cellular Therapies' Series A financing in 2002, beginning a relationship that continued through the company's development and commercialization of CAPLYTA for schizophrenia and bipolar depression.

Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion in 2025. Marcus served on its board from 2006 through the acquisition. The transaction provides a completed commercial milestone alongside MAP-D's still-developing research program, though the acquisition price is not a measure of Alexandria's investment proceeds.

Another portfolio company, Eikon Therapeutics, completed an upsized $381 million initial public offering in February 2026. Eikon is developing oncology medicines and houses its East Coast operations at the Alexandria Center for Life Science–NYC.

Those examples illustrate Alexandria's overlapping roles as a property owner, venture investor and research partner. The acquisition and IPO are completed financing events; MAP-D's value will depend on carrying out the planned study and establishing whether its combined data can produce useful findings for depression research.

Sources

Photo: Anna Shvets · Pexels Licence — source

Filed under Bio Space Brain & Mental Health

The Biotech Today briefing

Trials, approvals and the deals moving biotech, in your inbox. Free.

Unsubscribe from any email. See our privacy policy.